Gliomas are a heterogenous group of brain tumors with distinct biological and clinical properties. Despite advances in surgical techniques and clinical regimens, treatment of high-grade glioma remains challenging and carries dismal rates of therapeutic success and overall survival. Challenges include the molecular complexity of gliomas as well as inconsistencies in histopathological grading, resulting in an inaccurate prediction of disease progression and failure of standard therapy. The updated 2016 World Health Organization (WHO) classification of tumors of the central nervous system reflects a refinement of tumor diagnostics by integrating genotypic and phenotypic features, thereby narrowing defined subgroups. The new classification recommends the molecular diagnosis of IDH mutational status in gliomas. IDH-mutant gliomas are prompt to manifest the CpG Island Methylator Phenotype (G-CIMP).
10 cancer patients would be better classified by molecular taxonomy rather than by the current system based on the primary tissue of origin and stage of disease 6 .
The 2016 update to the WHO classification of tumors of the central nervous system (CNS) represents a shift in tumor diagnostics by integrating molecular and phenotypic features into the classification of tumors, and thereby narrowing defined subgroups 1 . Among the genetic alterations associated with diffuse gliomas, IDH mutation, histone H3 K27M status, and the integrity status of chromosomes 1 and 19 (1p and 19q ) are now integrated with the traditional histology/grade-based glioma classification 1, 7 . Gliomas harboring mutations in IDH1/2 as well as codeletion of 1p and 19q chromosome arms (1p/19q) have shown favorable prognostic and/or predictive values in relation to their counterparts (IDH-wildtype or 1p/19q intact or non-codel) [8] [9] [10] [11] [12] . Some epigenomic markers also have shown prognostic and/or predictive values 13 . Patients harboring gliomas that carry MGMT promoter methylation demonstrate increased overall survival (OS) and time to progression of the disease after treatment with temozolomide (TMZ) or radiation [14] [15] [16] [17] . MGMT promoter methylation status is used to guide therapeutic management for anaplastic gliomas with wildtype IDH1/2 and in glioblastoma (GBM) N-O-D-17-00175R2 7 of the elderly [14] [15] [16] [17] . Another important milestone highlighting the clinical importance of epigenetic signatures in gliomas was the discovery of the Glioma-CpG Island Methylator Phenotype (G-CIMP) 18 .
Patients carrying G-CIMP (G-CIMP positive) tumors have shown a better prognosis than those not carrying that phenotype (G-CIMP negative). G-CIMP positive (G-CIMP+) tumors was closely related to IDH-mutation. Nearly all IDH-mutant gliomas were G-CIMP+ and had a favorable prognosis 18, 19 .
However, comprehensive methylation profiling in a large cohort of glioma revealed that not all IDHmutant/G-CIMP+ tumors had the same prognosis 7 . Based on the extent of global methylation, this study uncovered two subsets of IDH-mutant/G-CIMP+ gliomas, one that presented a low degree of methylation and poorer outcome (G-CIMP-low) and another subset depicting high methylation and good OS as usually described for IDH-mutant/G-CIMP+ (G-CIMP-high) 7, 18, 19 . G-CIMP+ subsets (-low and -high) have shown distinct biological features and clinical implications that will be further explored in this review. Following a brief introduction to epigenomics in cancer and in neuro-oncology, we will detail the evolution of our understanding that led to the identification of the G-CIMP subsets. We will also describe how recent advances in methylation-based biomarkers that characterize gliomas may influence future basic and translational research. Our review will conclude with current and upcoming clinical applications, focusing on the potential translational importance of G-CIMP subsets.
Epigenetic modifications in cancer
Within the nucleus of a cell, the three-billion base pairs of the human DNA sequence are stored and organized as chromatin, which is made up of repeating units called nucleosomes. Nucleosomes are formed by octamers of histone proteins that are prone to chemical modifications such as methylation and acetylation. Several epigenetic mechanisms may operate in synchrony to modify the packaging of the genome, including DNA methylation, histone modifications, nucleosome remodeling, small and long non-coding RNA, protein:DNA interactions via chromatin modifying transcription factors, and three-N-O-D-17-00175R2 8 dimensional chromatin architecture 20 . The resulting epigenomic landscape determines the accessibility of regulatory elements to the DNA, thereby modulating the transcriptional regulation given by transcription factors 20 . Epigenetic mechanisms are implicated both in physiological and pathological events, such as tissue-specificity and carcinogenesis, respectively 20 . In the process of malignant transformation, gene inactivating mutations have been shown to control the epigenomic landscape, implying a crosstalk between the genome and the epigenome 21 . In the present review, we will focus on the first epigenetic modification to be linked to cancer and probably the most extensively studied epigenetic modification in mammals -DNA methylation 22 .
DNA methylation
DNA methylation status results from the action of methylating or demethylating enzymes. DNA methylation is the covalent transfer of methyl groups to the 5' position of the cytosine ring, mainly in the context of the dinucleotide cytosine-p-guanine (CpG), resulting in 5-methylcytosine (5mC). DNA methyltransferases (DNMTs), known as the DNA methylation "writer" enzymes, catalyze the transfer of the methyl group to 5' cytosine 23 . On the other hand, demethylation of 5mC is promoted by the TET1/2 (Ten-Eleven Translocation) methylcytosine dioxygenases, known as the DNA methylation "erasers", to generate 5-hydroxymethylcytosine (5hmC) 24 . Some stretches of DNA contain frequent CpG sites, defined as CpG islands (CGI), which are preferentially located at the 5' end of genes overlapping gene promoters 25 . CpG sites are also found in gene bodies and in other regions that are named, relative to their proximity to CGIs, as CpG shores (2kb regions flanking CGIs), CpG shelves (>2kb regions flanking CpG shores), and open sea regions (>4kb to the nearest CGIs) 26 . Intergenic regions that are enriched for CpG, but located in open seas, may encompass distal genomic regulatory elements such as enhancers, silencers and insulators. These transcriptional regulatory elements contain recognition sites for DNA-binding transcription factors, which function either to enhance or repress transcription. Specifically, enhancers are N-O-D-17-00175R2 9 elements able to activate target genes from distal locations independent of their orientation 27 , while insulators are boundary elements that possess the ability to block, or insulate, the signals of either enhancers or silencers 28 . The interplay between protein-DNA complexes defines the spatial organization of the human genome. As a result, chromatin loops are formed, mediated by insulator proteins such as the CCCTC-binding factor (CTCF), facilitating or blocking enhancer-promoter interactions. However, epigenomic alterations, such as gain of DNA methylation at the binding site of a regulatory element, could disrupt those interactions 29 .
Unlike the CpG sites dispersed throughout the genome that are usually methylated, CGIs located at promoter regions are generally unmethylated. In physiological conditions, CGI methylation usually occurs as a mechanism of gene repression in specific regions such as the inactive X-chromosome, imprinted genes and germline cell-specific genes 30 . In cancer, DNA methylation becomes aberrant and is mostly characterized by focal hypermethylation around the promoters of genes and gene bodies and global hypomethylation among non-promoter elements 31, 32 (Figure 1 ). Promoter hypermethylation is an important mechanism of epigenetic silencing of tumor suppressor genes 33, 34 . Methylation in nonpromoter regions is proposed to play a major role in intratumoral expression heterogeneity 35 . In contrast, global hypomethylation largely affects intergenic and intronic regions of the genome that may also result in chromosomal instability. Besides affecting gene expression and chromosomal status, aberrant DNA methylation also modulates isoform expression and facilitates mutational events in adult stem and progenitor cells 13, 32, 34 .
CIMP: CpG island methylator phenotype
Classically, CIMP is defined by genome-wide hypermethylation of CpG islands (CGI) ( Figure 1 ).
Tumors carrying this phenotype were first described and validated in the context of colorectal cancers, also known as colorectal CIMP 36, 37 . Since then, CIMP has also been described in several tumors, N-O-D-17-00175R2 including gliomas 18, 38 . Interestingly, the CIMP+ tumor subset exhibits distinct epidemiological, clinicopathological and molecular features in relation to its CIMP-counterpart. CIMP may have a prognostic significance (both favorable or unfavorable) in terms of OS or a predictive value of therapeutic response in certain tumors [38] [39] [40] . Despite tissue-specific differences, evidence suggests that CIMP may be a universal feature across different tumors. Addressing this issue, researchers applied a genome-wide unbiased and unsupervised hierarchical clustering of cancer-specific methylated CGI genes across 15 tumors types; however, gliomas were not included in the cohort 41 . They found a set of 89 shared hypermethylated CpG island probes that allowed the segregation of 12 tumor types into CIMP+ and CIMP-subgroups, according to the presence or absence of methylated probes, respectively 41 .
Glioma epigenomic molecular signatures G-CIMP: Glioma-CpG island methylator phenotype
The glioma-CIMP (G-CIMP) subtype was first described by Noushmehr et al. in GBM and was further validated in lower-grade glioma (LGG) 18, 19 . The G-CIMP+ subtype occurred frequently in LGG samples, whereas in GBM it was mostly associated with secondary or recurrent (treated) tumors 18, 19 . By integrating the DNA methylation data with four gene expression clusters previously described in GBM by Verhaak et al. (i.e. proneural, neural, classical, and mesenchymal) 42, 43 , the authors found that G-CIMP+ subtypes were highly enriched among the proneural subtypes and in younger patients, compared to G-CIMP-tumors. Later on, the G-CIMP subtype was also described in pediatric glioma patients 44 .
Importantly, G-CIMP+ was shown to be closely associated with IDH-mutant gliomas in several studies 18, 19 . The IDH-mutant non-codel cluster was further refined into two distinct subgroups, based on the extent of methylation: G-CIMP-low (6% of IDH-mutant) and G-CIMP-high (55% of IDH-mutant) with a low or high degree of DNA methylation, respectively 7 .
Prognostic value of G-CIMP+ and its subsets
The G-CIMP DNA methylation showed relevant prognostic value, independently of known OS predictors in adult diffuse glioma, such as grade and age 18 . The favorable prognostic value of G-CIMP+ in both LGGs and GBMs has been reported in many other studies 7, 18, 19, [44] [45] [46] . Notably, IDH-mutant G-CIMP+ GBM presented favorable survival and molecular similarities to LGG; on the other hand, LGG carrying IDH-wildtype G-CIMP-presented molecular and clinical behavior similar to GBM 7, 19, 44, 45 . The refinement of G-CIMP+ stratification revealed that not all IDH-mutant G-CIMP+ tumors had the same prognosis. The G-CIMP-low subset had the poorest OS among the IDH-mutant gliomas (median survival G-CIMP-low=2.7 years, G-CIMP-high=7.2 years, cox-regression p<0.001; and vs codel=7.9 years, p<0.001) resembling the behavior observed in IDH-wildtype gliomas (median survival 1.2 years) 7 .
Relationship between G-CIMP+/subsets and established prognostic and/or predictive molecular biomarkers
IDH mutations, codeletion of 1p/19q, MGMT promoter methylation, and G-CIMP+ are N-O-D-17-00175R2 12 independent, favorable prognostic biomarkers 47 . However, combining some of them has shown to improve their individual prognostic value 7, 18, 47 . For instance, patients harboring a triple combination of 1p19q codeletion, IDH mutation and MGMT methylation had significantly better OS than those carrying the MGMT methylation biomarker alone 48 . In addition, some of them (codeletion of 1p19q and MGMT promoter methylation) have also been established as predictive biomarkers and have been used in decision making for chemotherapy and/or radiation treatment 49, 50 . The relationship between G-CIMP and the aforementioned biomarkers will be explored in the following sections.
IDH mutation
One of the most relevant clinical discoveries in neuro-oncology involves IDH1 mutations in glioma for their role as a prognostic marker and potential as a drug target 1, 7, 10, 19, 44, [51] [52] [53] . The R132H IDH1 mutation, an amino acid substitution at a single arginine residue in the active site of the enzyme, is highly prevalent in grade II and III gliomas and appears in secondary GBMs, which develop from lower-grade tumors 10 . Although much less common, mutations in IDH2, the mitochondrial homolog of the cytosolic IDH1, have also been identified in gliomas 54 .
Due to the close relationship between IDH mutations and G-CIMP+, it was suggested that G-CIMP+ prognostic value was mainly due to its relation to IDH mutations 51 . The mechanisms associated with favorable prognosis in IDH-mutant G-CIMP+ tumors are still under investigation 13, 18 . However, a meta-analysis of a G-CIMP gene list with prior gene expression analyses suggested that G-CIMP+ tumors may be less aggressive because of silencing of key mesenchymal genes 18 .
The predictive value of IDH mutation for treatment response is still controversial 4,49,50,55 ; however, a phase III clinical trial reported that IDH-mutant anaplastic gliomas benefited from early combination of procarbazine, lomustine, and vincristine 50 . The predictive value of G-CIMP+ and its N-O-D-17-00175R2 13 subsets is still unknown.
1p/19q
1p/19q codel has an established favorable prognostic and predictive value in gliomas 46, 49 and is found exclusively in IDH-mutant tumors 56 . The interaction between 1p/19q status and G-CIMP+ has also been reported 12, 57 . IDH-mutant G-CIMP+ codel tumors, for example, were associated with a better OS than IDH-mutant G-CIMP+ non-codel (mean survival G-CIMP+ codel=9.9 years and G-CIMP+ non-codel=4.4 years) 57 . In our pan-glioma cohort, 9.1% of the IDH-mutant G-CIMP+ non-codel subgroup was represented by G-CIMP-low subtype with the remainder by the G-CIMP-high subtype 7 . As described, among the IDH-mutant G-CIMP+ non-codel tumors, the G-CIMP-high subset had similar survival to the IDH-mutant codel tumors 7 .
MGMT promoter methylation
MGMT promoter methylation has an established prognostic and predictive value and is used in therapeutic decision planning in gliomas 17, 49, 58 . MGMT promoter methylation has also been strongly associated with G-CIMP as well as with IDH mutation regardless of glioma grade 7, 11, [59] [60] [61] . From our published data, we estimated that among the TCGA IDH-mutant cohort, 91.8% of glioma specimens presented MGMT promoter methylation compared to 40.0% among IDH-wildtype tumors (p < 0.001) 7 .
Notably, G-CIMP-low samples presented a lower proportion of MGMT promoter methylation (68.0%) compared to G-CIMP-high (88.8%, p = 0.008, unpublished data) 7 .
Interestingly, better OS associated with MGMT promoter methylation was reported in patients harboring G-CIMP+ but not G-CIMP-GBM 47 . In addition, the predictive value of MGMT promoter methylation was described only in the context of IDH1/2 wildtype in anaplastic gliomas 49 . These findings prompt researchers to suggest that the prognostic significance and the predictive value of the MGMT N-O-D-17-00175R2
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promoter methylation in those tumors was dependent on the G-CIMP status and IDH mutation, respectively 47, 49, 60 . Moreover, some authors proposed that G-CIMP+ status may have a better prognostic value than MGMT promoter methylation in anaplastic oligodendroglial brain tumors 60 .
Potential drivers associated with G-CIMP
Putative driver mechanisms underpinning the aberrant CpG methylation that occurs in CIMP tumors are still under surveillance in gliomas. Some potential cancer-specific mutated driver genes encompass IDH1/2 and H3F3A 18, 19, 44, 62 . Hotspot mutations in IDH1/2 genes provoke IDH to display a neomorphic enzymatic activity that leads to the reduction of α Another consequence of IDH mutations is the alteration of other metabolic pathways components, such as the coenzyme NAD+ 66 . NAD+ has key role in intracellular signaling pathways implicated in cancer cell growth. It was shown that IDH-mutant cells presented reduced expression of NAPRT1 (nicotinate phosphoribosyltransferase 1), a rate-limiting enzyme within the NAD+ salvage system. Reduced expression of NAPRT1 led to lower basal NAD+ levels, rendering the IDH-mutant cell more vulnerable to death 66, 67 . Furthermore, IDH mutations also result in the methylation of histone markers that, by themselves, contribute to DNA methylation 68 . Histone H3F3A mutations were also reported to drive the global aberrant pattern of methylation in a subset of pediatric GBM by unknown mechanisms 44 .
Interestingly, in a subset of GBM, the authors found recurrent and mutually exclusive mutations either in 
G-CIMP+ subsets and glioma progression/recurrence
WHO grades II and III IDH-mutant non-codel (astrocytic) gliomas habitually recur and unpredictably undergo malignant transformation to highly aggressive and treatment-resistant grade IV GBM 1, 71 . Remarkably, the analysis of a small cohort of primary and recurrent matched tumor samples, composed of LGG and GBM, revealed that some G-CIMP-high tumors exhibited a demethylated pattern, after relapse, similar to those observed in G-CIMP-low gliomas, suggesting a progression from the G-CIMP-high to the G-CIMP-low subset 7 . A recent work from our own laboratory confirmed and expanded the finding of the epigenetic shift of G-CIMP-high to G-CIMP-low upon tumor recurrence in TCGA and non-TCGA samples 72 . Interestingly, G-CIMP-low at recurrence appeared in 12% of all gliomas and shared epigenomic features resembling IDH-wildtype primary GBM 72 . Genome-wide decreases in methylation levels associated with progression have also been reported by other studies 73, 74 .
The hypothesis that G-CIMP-high tumors may relapse as G-CIMP-low gliomas suggests that N-O-D-17-00175R2
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variations in DNA methylation could be key determinants of the mechanisms that drive glioma progression. Notably, the majority of CpG sites that underwent significant DNA demethylation in G-CIMP-low recurrent tumors were primarily found within intergenic (open sea) regions 7 (Figure 1 ).
CTCF, a methylation-sensitive insulator protein, has an important role in stabilizing enhancer-gene interactions in intergenic regions, as mentioned previously in this review. In IDH-mutant gliomas, it was shown that hypermethylation at CTCF binding sites reduced CTCF binding. The consequent loss of insulation led to aberrant enhancer-gene interaction that ultimately resulted in the upregulation of a glioma oncogene 75 . Since the discovery of IDH-mutant glioma subtypes, our group began to investigate the potential role of DNA methylation status at a single-base pair resolution, using Whole-Genome Bisulfite Sequencing (WGBS). Confirming previous data 7 , our unpublished findings revealed that, compared to G-CIMP-high (as well as to non-tumoral brain specimens), G-CIMP-low presented DNA hypomethylation at some CTCF binding sites. Collectively, these findings support the hypothesis that the loss of methylation at the CTCF binding sites will also influence chromatin architecture mediated by the insulator binding disruption that in turn will deregulate genes nearby ( Figure 3 ) (Sabedot TS et al, unpublished data). We also found that the hypomethylated intergenic regions were enriched for OLIG2
and SOX-family motif binding sites 7 , which have been described as neurodevelopmental transcription factors essential for GBM propagation 76 . SOX-family genes are transcription factors that are also involved in the induction and maintenance of stem cell pluripotency 77 , promote self-renewal of neural stem cells in the nervous system 78 , and within brain tumors regulate the plasticity between glioma stem cell and non-stem cell states 79 Figure 4 ).
G-CIMP detection
The 
Epigenomic and chromatin targeted-therapies
Epigenetic mechanisms are heritable and potentially actionable, making them an attractive target for the treatment of diseases, including cancer 80 . Many of the epigenome-targeting drugs have proved beneficial and safe in hematologic malignancies 81, 82 . However, studies in solid tumors are limited 52, 80, 83 .
Epigenetic drugs approved or in clinical trials have been thoroughly explored in recently published reviews 52, 80, 84 .
In gliomas, few trials from this class have been completed 81, 82, 84, 85 . To our knowledge, there are N-O-D-17-00175R2
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no clinical trials specifically addressing G-CIMP+ subtypes. However, preclinical and clinical studies using drugs targeting DNA methylation directly, or the mechanisms involved in G-CIMP, are underway.
Representing epigenetic drugs with broad actions are hypomethylating agents such as the inhibitors of DNA methyltransferase (DNMT), the histone deacetylase (HDAC) and the bromodomain and extraterminal motif proteins (e.g. BRD4 inhibitor) 80 .
DNMT inhibitors or DNA demethylating agents (e.g., 5-Azacytidine, 5-Aza-2-deoxycytidinedecitabine) promote dose-dependent global demethylation activity by depleting or degrading the DNA methyltransferases. This may reverse aberrant expression of genes related to nearly all pathways involved in cancer initiation and progression (i.e., tumor suppressor genes, oncogenes, genes associated with stemness or pluripotency, apoptosis, cell-cycle and, immune response) 86, 87 . Moreover, DNMT inhibitors were also shown to reverse tumoral immune evasion through viral infection mimicry and up-regulation of viral defense pathways [88] [89] [90] . For instance, in an IDH1-mutant glioma xenograft, low doses of the demethylating agent, decitabine, restored the activity of DNMT1 and, consequently, reversed DNA methylation marks in promoters of differentiating genes. This change resulted in the loss of stem-like features and in the arrest of the glioma growth in that model 91 . Although preclinical studies using these drugs in gliomas seem promising, a corresponding clinical trial using decitabine on adult glioma has not been reported. Considering the potential adverse impact of loss of methylation in the progression or recurrence of gliomas, reported previously 72, 73 , it seems reasonable to take G-CIMP subsets into account during clinical trial design. Targeting IDH-mutant tumors, including G-CIMP+ gliomas, with IDH-mutant enzyme inhibiting agents is currently under investigation in clinical trials 52, 66, 80 . The mechanistic intent of these drugs involve the metabolic pathways altered in IDH-mutant tumors (i.e. decrease of 2-HG in hematologic or salvage of NAD+ in solid tumors) 66 . However, a preclinical study has not identified a decrease or epigenetic changes in IDH-mutant cancer initiating cells exposed to an IDH-R132 inhibitor drug despite marked reduction in 2-HG 66 . They postulated that the activity of this class of drug may be limited to a subset of tumors. Moreover, NAD+ metabolic depletion was recently shown to be an attractive therapeutic target in IDH1-mutant cells vulnerable to a cytotoxic response when exposed to a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor. The same response was not seen in IDH1wildtype cell lines 66 ; however, a later preclinical model demonstrated that NAMPT inhibitors enhanced the cytotoxic effects of TMZ in GBM cells 93 .
Immune modulation is also affected by epigenomic alterations and has been shown to be an attractive target for pharmacotherapy in cancer 94 . The identification and targeting of disease-specific neoantigens has demonstrated success in other diseases renewing excitement for immunotherapy in glioma. An immunogenic epitope vaccine targeting mutant IDH1 in glioma with promising preclinical work is now in phase I clinical trials 95, 96 . Several other clinical trials are underway in glioma including phase III targeted immunotherapy trials 97 . The use of immune checkpoint inhibitors targeting programmed cell death protein 1 (PD1) and/or its ligand 1 (PD-L1) has also shown activity in several cancer types and is currently being tested in GBM clinical trials. The PD-L1 promoter methylation and PD-L1 lower expression in IDH-mutant gliomas compared to IDH-wildtype point to an epigenetic regulation of PD-L1 and indicate that patient harboring IDH-mutant gliomas may not benefit from the N-O-D-17-00175R2
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monotherapy with drug targeting the blocking of the PD1/PD-L1 pathway 98 .
Co-administration of epigenomic agents (e.g., DNA-demethylating agents and HDAC inhibitors) has demonstrated improved efficacy of immunotherapy in many tumor types by increasing tumoral immune-response, enhancing the expression of immune blockade checkpoints, and by reducing cellular adaptation that leads to drug resistance 99 . Given the potential epigenetic regulation of PD-L1 expression, patients harboring IDH-mutant (G-CIMP+) tumors may benefit from combined treatment modalities including demethylating agents and PD1/PD-L1 inhibitors. The relationship between G-CIMP subsets and response to immunotherapy, either as a predictive marker or epigenetic therapy target, is largely unknown and worthy of further investigation. Remarkably, the identification of a methylation-based classifier of glioma specimens enabled the researchers to capture already known prognostic markers such as IDH mutation and 1p19q codeletion 7 .
Final remarks and perspectives
In addition, it uniquely enabled the identification of a subset of tumors within the IDH-mutant/G-CIMP+ group (i.e., G-CIMP-low) that presented a prognostic disadvantage in relation to its counterparts (IDHmutant G-CIMP-high non-codels and codels). In addition to refining glioma classification, the identification of G-CIMP+ subsets also shed light on the role of demethylation of specific genes in the pathogenesis of glioma progression, independently of grade or IDH status 72 .
In summary, the detection of G-CIMP+ and subsets (-high and -low) builds on the 2016 WHO molecular effort to further refine glioma classification ( Figure 5 ) and provides insight into disease course and treatment opportunity 72 . The prognostic significance of G-CIMP+ across all glioma types has been confirmed in many studies 7, 18, 46, 47 . Moreover, in addition to their prognostic value, the identification of G-CIMP subsets led us to define predictive candidate biomarkers for tumor recurrence as G-CIMP-low 72 . It is possible that, as for other established therapeutic predictive markers in gliomas, such as 1p/19q codeletion and MGMT promoter methylation, G-CIMP+ subsets will be used for patient counseling and be part of algorithms used for clinical trial design and for therapeutic decisions 4 . However, the utility of these classifiers and biomarkers in planning treatment strategies and designing clinical trials remains to be fully validated. 
